Tejara Capital Ltd reported 5.3% ownership of Cardiol Therapeutics, representing 6,382,551 Class A common shares. The position is certified as held in the ordinary course and not for changing or influencing control, giving investors the stated basis for its passive classification.

Key Highlights

  • Tejara Capital Limited manages Trefoil Select Funds SPC-Stylus SP, which is registered in Cayman.
  • Miyan Mansur Mannan signed the ownership report as director on Sep 23, 2026.
  • Tejara undertook to provide Commission staff with requested information under the certification.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. Tejara Capital Ltd reported ownership of 5.3% of Cardiol Therapeutics, covering 6,382,551 Class A common shares. The position was described as held in the ordinary course without an intent to change or influence control.

Tejara Reports 6,382,551 Class A Shares

Tejara Capital Limited is authorised by the FCA in the United Kingdom as a fund manager. The reported position relates to Trefoil Select Funds SPC-Stylus SP, which is registered in Cayman. The ownership information appears on a Schedule 13G/A under Rule 13d-1(b). The report identifies 5.3% ownership of Cardiol Therapeutics.

Passive Ownership Certification

The certification says the securities were acquired and held in the ordinary course of business. It also states that the position was not acquired or held to change or influence Cardiol Therapeutics’ control, nor in connection with a transaction intended to do so. Tejara further certified that the UK regulatory framework applying to an FCA-authorised Fund Manager is substantially comparable to the corresponding U.S. framework.